Get the Stockscreener App
1.05
3.67%
-0.04
After Hours:
1.05
Boundless Bio Inc stock is traded at $1.05, with a volume of 121.60K.
It is down -3.67% in the last 24 hours and down -32.26% over the past month.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
See More
Previous Close:
$1.09
Open:
$1.07
24h Volume:
121.60K
Relative Volume:
1.21
Market Cap:
$26.42M
Revenue:
-
Net Income/Loss:
$-61.06M
P/E Ratio:
-0.0733
EPS:
-14.3261
Net Cash Flow:
$-59.30M
1W Performance:
-11.02%
1M Performance:
-32.26%
6M Performance:
-57.32%
1Y Performance:
-85.52%
1-Day Range:
$1.04
$1.124
1-Week Range:
$1.04
$1.195
52-Week Range:
$1.04
$7.55
Boundless Bio Inc Stock (BOLD) Company Profile
Name
Boundless Bio Inc
Sector
Industry
Phone
(858) 766-9912
Address
10955 ALEXANDRIA WAY, SAN DIEGO
Compare BOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLD
Boundless Bio Inc
|
1.05 | 26.42M | 0 | -61.06M | -59.30M | -14.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-13-24 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-22-24 | Initiated | Guggenheim | Buy |
| Apr-22-24 | Initiated | Leerink Partners | Outperform |
| Apr-22-24 | Initiated | Piper Sandler | Overweight |
View All
Boundless Bio Inc Stock (BOLD) Latest News
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Boundless Bio Showcases Revolutionary ecDNA Cancer Treatment at Major Goldman Sachs Healthcare Conference - Stock Titan
H.C. Wainwright initiates Boundless Bio stock with buy rating - Investing.com
HC Wainwright & Co. Initiates Coverage of Boundless Bio (BOLD) with Buy Recommendation - Nasdaq
H.C. Wainwright initiates Boundless Bio stock with buy rating By Investing.com - Investing.com India
Boundless Bio initiated with a Buy at H.C. Wainwright - TipRanks
Boundless Bio Inc. Reports Q1 2025 Financial Results - TipRanks
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
Leerink cuts Boundless Bio stock rating on program setback By Investing.com - Investing.com Nigeria
Leerink cuts Boundless Bio stock rating on program setback - Investing.com
Leerink Partners Downgrades Boundless Bio to Market Perform From Outperform, Adjusts PT to $3 From $15 - marketscreener.com
Hold Rating Issued for Boundless Bio Inc. Amid Strategic Setbacks and Delayed Program Validations - TipRanks
Boundless Bio downgraded to Market Perform from Outperform at Leerink - TipRanks
Liposarcoma Clinical Trial Analysis: Key Insights into Rich - GlobeNewswire
Boundless Bio changes plans for cancer drug after toxicity issues - Endpoints News
Boundless Bio To Reduce Its Workforce By About One-third - Nasdaq
Boundless Bio Announces Portfolio Prioritization And Runway Extension - marketscreener.com
Boundless Bio Announces Major Workforce Reduction Strategy - TipRanks
Boundless Bio's Portfolio Adjustments and Streamlined Operations Boost Cash Runway - marketscreener.com
Boundless Bio discontinuing BBI-355 and BBI-825 programs - TipRanks
Boundless Bio Announces Portfolio Prioritization and Extended Operating Runway Through 2028 with Focus on Novel Combination Therapy and New Development Candidate - Nasdaq
Boundless Bio Announces Portfolio Prioritization and Runway Extension - The Manila Times
Silvercrest Asset Management Group Inc. Announces $25 Million Common Stock Repurchase Program - The Manila Times
Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability - Endpoints News
Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know - MSN
Boundless Bio reports R&D pipeline progress - The Pharma Letter
Boundless Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times
Boundless Bio Reports Q1 2025 Financial Results and Progress on BBI-355 Phase 1/2 Trial and Kinesin Program Development - Nasdaq
New Strong Sell Stocks for May 1st - The Globe and Mail
Boundless Bio’s 2024 Financial Results and Strategic Progress - MSN
Boundless Bio stock plunges to 52-week low of $1.41 - Investing.com Australia
Boundless Bio to Participate in the Needham Virtual Healthcare Conference - TradingView
Boundless Bio stock plunges to 52-week low of $1.41 By Investing.com - Investing.com UK
Boundless Bio plans $14.5M stock sale via Jefferies By Investing.com - Investing.com Australia
Boundless Bio plans $14.5M stock sale via Jefferies - Investing.com India
Boundless Bio Inc Files For Mixed Shelf Of Up To $400 MillionSEC Filing - MarketScreener
Boundless Bio Inc. (BOLD) reports earnings - Quartz
Boundless Bio Inc Stock (BOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):